Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20062940 | 0.76 | HCRTR1 (0.40) | ROCK1HCRTR1HCRTR2GRM4CYP17A1 | |
| SCHEMBL20681919 | 0.71 | EP300 (0.44) | HTTKDM4ELMNA | |
| SCHEMBL17716006 | 0.68 | MKNK1 (0.48) | ROCK1HCRTR1HCRTR2GRM4PIK3CA | |
| SCHEMBL20681830 | 0.68 | GAA (0.42) | HTTKDM4ELMNA | |
| SCHEMBL20072041 | 0.67 | L3MBTL1 (0.45) | CYP17A1KDM4ELMNA | |
| SCHEMBL19533417 | 0.66 | CDK2 (0.67) | ROCK1 | |
| SCHEMBL23697527 | 0.66 | ALDH1A1 (0.48) | HTTKDM4ELMNA | |
| SCHEMBL21308705 | 0.66 | IDH1 (0.39) | ROCK1GRM4PIK3CAMTORHTT | |
| SCHEMBL21554382 | 0.65 | ROCK1 (0.68) | ROCK1HTT | |
| SCHEMBL20071965 | 0.64 | USP2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10541260-B2 | Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus | CANON KABUSHIKI KAISHA (JP) | 2020-01-21 | — | — | US | disclosed |
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | CANON KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | BRD1, DRD1, NR2E3 | ROCK1 2427/4885HCRTR1 367/4885HCRTR2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.